Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 15

Results For "design"

1487 News Found

FDA issues warning letter to Philips over manufacturing and quality system deficiencies
Medical Device | October 31, 2025

FDA issues warning letter to Philips over manufacturing and quality system deficiencies

The FDA’s review also revealed delays in Philips’ internal investigations, with 54 inquiries failing to meet targeted completion dates—23 of which were delayed by more than 100 days


Lupin Digital Health launches VITALYFE
Healthcare | October 31, 2025

Lupin Digital Health launches VITALYFE

AI-powered cardiometabolic wellness platform for India’s workforce


LillyDirect and Walmart Pharmacy launch first retail pick-up option with direct-to-consumer pricing for Zepbound
Supply Chain | October 30, 2025

LillyDirect and Walmart Pharmacy launch first retail pick-up option with direct-to-consumer pricing for Zepbound

Walmart, with nearly 4,600 pharmacies nationwide, will serve as the first in-store pickup pharmacy for LillyDirect's self-pay single-dose vials


Lilly and NVIDIA join forces to build world’s most powerful AI supercomputer for drug discovery
R&D | October 30, 2025

Lilly and NVIDIA join forces to build world’s most powerful AI supercomputer for drug discovery

New AI capabilities will help scientists identify, optimize, and validate new molecules. Additional applications include manufacturing, medical imaging, and enterprise AI agents


Allergan Aesthetics and Girls inspire the next generation of women leaders in STEM
News | October 30, 2025

Allergan Aesthetics and Girls inspire the next generation of women leaders in STEM

Allergan Aesthetics reaffirms commitment to empowering girls through STEM mentorship and education initiatives


FDA grants fast track status to Heidelberg Pharma’s Amanitin-based ADC candidate for multiple myeloma
Drug Approval | October 29, 2025

FDA grants fast track status to Heidelberg Pharma’s Amanitin-based ADC candidate for multiple myeloma

The Fast Track Designation was supported by nonclinical data as well as clinical results from the ongoing Phase I/IIa trial evaluating the safety and tolerability


MIRA Pharmaceuticals advances oral Ketamir-2 into Phase 1 MAD study for chemotherapy-induced neuropathic pain
Clinical Trials | October 29, 2025

MIRA Pharmaceuticals advances oral Ketamir-2 into Phase 1 MAD study for chemotherapy-induced neuropathic pain

Advancing toward Phase 2a evaluation in chemotherapy-related pain, a condition with no approved treatments and potential for FDA Fast Track designation


Orion secures license to Abzena’s next-generation cancer antibody
R&D | October 29, 2025

Orion secures license to Abzena’s next-generation cancer antibody

The antibody was designed and developed at Abzena’s Cambridge, UK,